A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis

NCT03384745 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

313

Enrollment

INDUSTRY

Sponsor class

Conditions

Psoriasis

Interventions

DRUG: M1095 (Sonelokimab)
DRUG: Placebo
DRUG: Secukinumab

Sponsor

Bond Avillion 2 Development LP

Collaborators

[object Object]